The successful candidate has experience with standard molecular and cell culturing techniques, and preferably some experience working in a company. Experience with culture, differentiation of iPSCs/stem cells and Article 12 - Article 9 is an advantage.
Your tasks include: Culture cells, perform iTOP in various cell types, measure outcome with viability and gene-editing assays, data-analysis, presention of results and general lab duties like the preparation of stock solutions and keeping the lab well stocked.
The candidate needs to have a HLO diploma, excellent interpersonal and communicative skills, and proficiency in English (oral/written).
Appointment: Full-time (40-hours/week)
Starting date: Dec 2020/Jan 2021
Duration: One year with possible extension after positive evaluation
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. The iTOP intracellular delivery technology is based on a combination of small molecule compounds which forces the uptake of large gulps of extracellular fluid (containing the bioactive molecules) by the cell (D’Astolfo et al. 2015, Cell 161: 674-690). Once inside, the vesicles release their content into the cytoplasm, where the bioactive molecules (like gene editing systems) can exert their therapeutic action.
The goal of NTrans Technologies is to further develop the iTOP transduction technology into a therapeutic platform for the treatment of (genetic) disorders and cancer.